Cea Garcia, Jorge , Maraver, Francisco Marquez , Rodriguez, M. Carmen Rubio , Rios-Pena, Laura , Jimenez, Inmaculada Rodriguez
No
Indian J. Gynecol. Oncol.
Article
Científica
01/03/2024
001141894700001
PurposeTo achieve the internal validation of predictive models for recurrence-free survival and risk of recurrence in patients with cervical cancer at any stage.MethodsA retrospective analysis of a prospectively collected data was conducted between January 2010 and January 2019 on 229 women with cervical cancer. We performed a survival analysis using the Kaplan-Meier method and, finally, developed a Cox model. We also elaborated a binomial generalized linear model for the occurrence of recurrence.ResultsMedian recurrence-free survival was 44.37 months (IQR = 44.81 months; R = 1-252). A reduction in the likelihood of recurrence-free survival of 40% was observed in the first 25 months of follow-up and, from that moment, it continued to decline gradually reaching the value of 9.8% at 6 and a half years, remaining stable from that moment until the end of the follow-up. We employed a Cox model with a predictive capacity of 78% and based on predictors as follow: maximum tumor diameter, PET-CT findings, and weekly dose of cisplatin. Thirteen ninety-seven percent of patients developed, at least, 1 recurrence during the follow-up time. We employed a binomial generalized linear model with a predictive capacity of 80% and based on predictors as follow: FIGO stage and experience of adverse effects.ConclusionsThirteen ninety-seven percent of patients with cervical cancer developed, at least, 1 recurrence. The highest reduction in the likelihood of recurrence-free survival was observed in the first 25 months of the follow-up duration. We developed solid models that, once externally validated, might provide useful prognostic information for both patients and oncologists at first consultation.
Models; Neoplasm recurrence; Statistical; Survival analysis; Uterine cervical neoplasms